Marks P, Manna V K, Gibson J R
Wellcome Research Laboratories, Beckenham, UK.
J Int Med Res. 1989;17 Suppl 2:3B-8B.
Twenty-four healthy volunteers were entered into a double-blind, crossover study conducted to establish the time of onset of action and the time to peak activity of acrivastine in suppressing the weal and flare responses to intradermally injected histamine. Volunteers received single doses of 8 mg acrivastine and placebo according to a fully randomized, balanced treatment plan. Acrivastine significantly (P less than 0.001) reduced both the weal and flare responses induced by histamine challenge 30 min after oral dosing, as compared with placebo. Peak inhibition of the flare response was seen at 90 min, and maximal suppression of the weal response occurred at 120 min after administration of acrivastine.
24名健康志愿者参与了一项双盲交叉研究，该研究旨在确定阿伐斯汀抑制皮内注射组胺引起的风团和红晕反应的起效时间及达到最大活性的时间。志愿者根据完全随机、均衡的治疗方案接受单剂量8毫克阿伐斯汀和安慰剂。与安慰剂相比，口服给药30分钟后，阿伐斯汀能显著（P<0.001）降低组胺激发引起的风团和红晕反应。口服阿伐斯汀后90分钟出现对红晕反应的最大抑制，120分钟出现对风团反应的最大抑制。
